The Federal Grant Drought of 2026: NIH Awards Down 66%, NSF at 20% of Normal, and What to Do About It

Halfway through fiscal year 2026, the National Institutes of Health has posted 14 notices of funding opportunity. In fiscal year 2024, by the same date, the number was 756.

That single comparison captures the scale of what has become the most severe contraction in federal research funding in modern history. Across every major grant-making agency — NIH, NSF, DOE, DOL — the pipeline has narrowed dramatically, and the effects are rippling through universities, nonprofits, small businesses, and the communities they serve. This is not a temporary budget hiccup. It is a structural transformation of the federal grants landscape, driven by simultaneous forces — policy shifts, staffing losses, legislative delays, and a deliberate reorientation of what the government is willing to fund.

The Numbers Tell a Stark Story

Start with grants.gov, the federal government's central clearinghouse. In February 2025, the platform listed roughly 2,400 active grant opportunities. By February 2026, that number had fallen to approximately 1,600 — a 33% decline. The drop was concentrated in posted opportunities (grants actively accepting applications), which fell more than 50%, from about 1,850 to 900. Forecasted opportunities rose modestly, suggesting agencies are planning future solicitations but haven't opened them yet.

The agency-level data is worse.

NIH awarded 66% fewer grants through late February 2026 compared to the same period in fiscal years 2021 through 2024, according to an Association of American Universities analysis. Dollar amounts were down 54%. The grant success rate has plummeted to roughly 13% — a historic low for an agency that typically funds around 20-25% of reviewed applications. Nearly 4,400 NIH employees have departed since early 2025 through buyouts, early retirements, and layoffs, hollowing out the program officer corps that manages the review and award pipeline.

NSF has awarded just 613 grants this fiscal year — approximately 20% of the level at this point in each of fiscal years 2021 through 2024. The agency lost its director when Sethuraman Panchanathan resigned in April 2025, and no permanent replacement has been nominated. Staff reductions have hit some directorates hard: the biology directorate, for example, now operates with 40% fewer program officers. On top of the staffing crisis, DOGE terminated 1,752 NSF grants worth $1.4 billion, with the STEM Education directorate alone losing 839 grants worth $888 million.

The contraction extends beyond the research agencies. The Department of Labor, Department of Education, EPA, and other grant-making agencies have all reduced the number and scope of new funding announcements, reflecting both the administration's policy priorities and the practical consequences of workforce reductions across the federal government.

NIH's Forward Funding Gamble

Buried beneath the headline numbers is a structural shift that will reshape biomedical research funding for years: NIH has moved to a "forward funding" model, awarding larger lump sums for multi-year grants rather than the traditional annual disbursements.

The result is striking. The average competitive grant size has nearly doubled, from roughly $472,000 to $830,000. On paper, that looks generous. In practice, it means the same appropriated dollars are spread across far fewer awards. A researcher who previously competed against four applicants for each available slot now competes against eight or more.

This model has a certain administrative logic — it reduces the annual re-approval burden on understaffed program offices — but it fundamentally changes who gets funded. Early-career researchers, who historically relied on smaller, more numerous awards to build a track record, face a landscape where each application carries higher stakes and lower odds. Emily Bruce, a microbiology professor at the University of Vermont, has applied for 40 grants over five years and received just three small awards, with 11 applications still awaiting decisions. Her experience is becoming the norm, not the exception.

A STAT survey published April 30 found that physician-scientists are increasingly pivoting from research toward clinical patient care to generate revenue for their institutions. When a 13% success rate makes grant income unreliable, the rational economic decision is to see more patients, not write more proposals. The long-term cost — fewer clinical researchers, slower translation of bench science to bedside treatments — won't show up in budget spreadsheets for years.

Compressed Windows and Political Oversight

The drought isn't just about fewer opportunities — it's about less time to respond to the ones that remain. Grants that were open for six months or longer in previous funding cycles now close within weeks. The compressed windows demand that applicant organizations maintain a state of constant readiness: pre-written boilerplate, pre-identified collaborators, pre-built budgets. Institutions without dedicated sponsored programs offices are at a severe disadvantage.

The speed pressure compounds another change: Executive Order 14332, signed in August 2025, requires each agency head to designate a senior political appointee to review funding announcements and award recommendations. That appointee must confirm that each award "demonstrably advances presidential policy priorities" and aligns with the national interest. Peer review recommendations are explicitly advisory — political appointees can override them.

In practical terms, this means that even a perfectly scored proposal can be deprioritized if it doesn't align with the administration's stated focus areas: artificial intelligence, workforce development, energy expansion, infrastructure beautification, and deregulation. References to DEI, environmental justice, climate science, and underserved communities have been systematically removed from new notices of funding opportunity. Researchers whose work touches those areas face a double bind: fewer opportunities and an ideological filter on the ones that exist.

The Cascade Effect on Private Philanthropy

The federal contraction has triggered a secondary crisis in private grantmaking. According to a NonProfit Times analysis, 87% of foundation leaders report increased demand for funding, while a third of nonprofits report federal funding declines. With 1.5 million nonprofits now competing for roughly 100,000 active funders, the arithmetic is unforgiving.

Foundation giving is projected to grow 5-7% annually in 2026, but that increase cannot compensate for the scale of federal losses. The NIH alone distributes roughly $35 billion in annual grants. Total U.S. foundation giving is approximately $100 billion across all sectors, and most of it is already committed. The idea that private philanthropy can meaningfully replace federal research and social program funding is a category error — it confuses the supplement with the source.

What is happening instead is a strategic reorientation. Some foundations — including the GitLab Foundation and OpenAI's AI for Economic Opportunity Fund — are stepping into specific gaps with targeted programs. Others are increasing rapid-response grantmaking to organizations whose federal funding was abruptly terminated. But these efforts, however well-designed, operate at a fraction of the scale needed to offset the federal contraction.

What Grant Seekers Should Do Right Now

The temptation in a drought is to submit more applications and hope the volume compensates for lower odds. The data suggests a different approach.

Monitor daily, not monthly. With application windows shrinking from months to weeks, the organizations that win will be the ones that see opportunities first. Set up automated alerts on grants.gov, subscribe to agency listservs, and check research.gov and the NIH Guide weekly at minimum. The 50% drop in posted opportunities means each one carries more weight — missing a window is more costly than it used to be.

Align language with current priorities. The administration has made its funding preferences explicit: AI, workforce development, energy, national security, and measurable outcomes. Proposals that can credibly connect their work to these themes — without contorting their actual research — will have an advantage. This isn't about abandoning important work; it's about framing it in terms that survive political review.

Diversify across agency and sector. Researchers who have historically applied exclusively to NIH or NSF should explore DOE, DARPA, ARPA-H, and the newly reauthorized SBIR/STTR programs. The Department of War released over 90 SBIR/STTR topics within a week of the April reauthorization, and NASA's 2026 BAA is open through September 2027. State-level funding is expanding in several states — Colorado, California, New York, and Massachusetts have all increased research grant programs as a partial hedge against federal cuts.

Build proposal infrastructure before you need it. The organizations winning in compressed timelines are the ones with modular proposal templates, pre-negotiated subaward agreements, current biosketches, and approved budgets ready to customize. If your sponsored programs office hasn't updated its rapid-response capabilities, that conversation should happen now.

Track the FY2027 timeline. The current appropriations expire September 30, 2026. The administration's FY2027 budget request proposed a 55% cut to NSF — from $8.75 billion to $3.9 billion — which Congress rejected for FY2026 but which will return as a negotiating position. The indirect cost rate fight, the DOGE termination authorities, and the political oversight framework established by EO 14332 will all be contested again in the next appropriations cycle. Organizations that engage their Congressional delegations now — with specific data on local research impact — will be better positioned when those fights resume.

A Structural Shift, Not a Cycle

Previous federal funding contractions — after sequestration in 2013, during government shutdowns — were temporary disruptions to a system that snapped back. This one is different. The combination of intentional policy reorientation, staffing losses that will take years to reverse, structural changes like forward funding, and political oversight mechanisms that didn't previously exist means the pre-2025 funding landscape isn't coming back in its previous form.

That doesn't mean the landscape is permanently hostile — $8.75 billion still flows through NSF, and NIH's roughly $48 billion budget remains the world's largest public investment in biomedical research. But the rules of engagement have changed, the competition has intensified, and the organizations that adapt fastest will capture a disproportionate share of what's available.

For researchers and nonprofits navigating this compressed, competitive environment, tools like Granted can help you find the opportunities that match your work, build proposals aligned with current priorities, and move faster than the shrinking windows allow.